相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rates of Malignancy Associated With Juvenile Idiopathic Arthritis and Its Treatment
Timothy Beukelman et al.
ARTHRITIS AND RHEUMATISM (2012)
Tumor Necrosis Factor Therapy and the Risk of Serious Infection and Malignancy in Patients With Early Rheumatoid Arthritis A Meta-Analysis of Randomized Controlled Trials
Andrew E. Thompson et al.
ARTHRITIS AND RHEUMATISM (2011)
Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study
Sarika Ogale et al.
BMC MUSCULOSKELETAL DISORDERS (2011)
Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease
Harminder Singh et al.
GASTROENTEROLOGY (2011)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
Nonmelanoma Skin Cancer in Inflammatory Bowel Disease: A Review
Millie D. Long et al.
INFLAMMATORY BOWEL DISEASES (2011)
Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data
Johan Askling et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems
Lisa J. Herrinton et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel Disease
Millie D. Long et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
Immortal time bias in estimates of mortality among infliximab-treated patients with Crohn's disease
James D. Lewis
GUT (2010)
Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
T. Bongartz et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Cancer Risk in Patients With Rheumatoid Arthritis Treated With Anti-Tumor Necrosis Factor α Therapies Does the Risk Change With the Time Since Start of Treatment?
Johan Askling et al.
ARTHRITIS AND RHEUMATISM (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Laurent Beaugerie et al.
LANCET (2009)
Screening differences and risk of cervical cancer in inflammatory bowel disease
S. Hutfless et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials
Laurent Peyrin-Biroulet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Crohn's disease patients' risk-benefit preferences:: Serious adverse event risks versus treatment efficacy
F. Reed Johnson et al.
GASTROENTEROLOGY (2007)
Biologic treatment of rheumatoid arthritis and the risk of malignancy - Analyses from a large US observational study
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders
M. H. Buch et al.
RHEUMATOLOGY (2007)
Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data
Soko Setoguchi et al.
CANCER CAUSES & CONTROL (2007)
The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation
Frederick Wolfe et al.
ARTHRITIS AND RHEUMATISM (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis
E Baecklund et al.
ARTHRITIS AND RHEUMATISM (2006)
Indications for propensity scores and review of their use in pharmacoepidemiology
RJ Glynn et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2006)
Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center
SK Agarwal et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2005)
The risk of lymphoma development in autoimmune diseases - A meta-analysis
E Zintzaras et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
J Askling et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Inflammatory bowel disease is not associated with an increased risk of lymphoma
JD Lewis et al.
GASTROENTEROLOGY (2001)
Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma
JD Lewis et al.
GASTROENTEROLOGY (2000)
分享论文
